Exousia Pro Announces Pivotal Corporate Milestones
Exousia Pro, Inc. (OTCPK: MAJI), a clinical-stage biotechnology leader specializing in proprietary exosome-based delivery systems, has announced several pivotal corporate milestones aimed at enhancing shareholder value and expanding the company’s commercial footprint.
Major Capital Structure Optimization
Exousia Pro has successfully completed the cancellation of derivative securities convertible into 47 million shares of Common Stock. This substantial reduction was achieved through a strategic mediation and exchange agreement. In lieu of a prolonged legal dispute, the Company exchanged 2 million shares of LMMY for the cancellation of Series B Preferred shares (which were convertible into the 47 million common shares). As part of this transaction, Ludwig Enterprises, Inc. has entered into a formal lock-up and leak-out agreement regarding the LMMY shares, ensuring current and future market stability.
For Indian investors looking to navigate the complexities of the US stock market, it’s essential to stay informed about US stock market news and trends. Additionally, understanding the OTC markets can provide valuable insights into the performance of companies like Exousia Pro.
Telehealth Acquisition Momentum and Revenue Scaling
The Company is aggressively moving forward with Definitive Agreements to acquire three telehealth entities previously under Letter of Intent (LOI). Recent due diligence reveals exceptional growth: Revenue Growth: One target entity has scaled monthly revenue from $80,000 to $135,000 since December.
Strategic Partnership: Beginning in April, this entity will serve as the exclusive supplier for 1,900 clinics. With an anticipated volume of 2,000 prescriptions per day at a rate of $4.00 per script, the Company anticipates a transformative impact on its consolidated revenue. This growth is reminiscent of the Indian telehealth market trends, which have seen significant expansion in recent years.
Commitment to Shareholder Value: Reg A & Buyback Program
Exousia Pro is currently utilizing a Regulation A offering to raise targeted capital for product launches and final testing. Management remains steadfast in its pledge to maintain a lean share structure. Upon reaching the funding goal of $200,000–$300,000, the Company intends to move to leverage its LMMY holdings and internal cash flow to fund a Share Buyback Program, thereby serving to neutralize any dilution resulting from the current offering.
Indian investors interested in biotechnology stocks should consider the potential impact of regulatory environments on company performance. The US SEC regulations play a crucial role in shaping the biotech industry, and understanding these regulations can help investors make informed decisions.
Corporate Rebranding: Nextel Medical Corp.
Reflecting a new era of growth and a distinct market identity, the Company has filed for a name change with the State of Florida. The Company will transition from Exousia Pro, Inc. to Nextel Medical Corp. Shareholders may track the progress of this filing at www.sunbiz.org.
Litigation Update and Mediation
A mediation session is scheduled for Friday, March 13, 2026, at the request of the defendants. Management enters this session with a position of strength, seeking the full cancellation of additional restricted shares and further concessions to protect the float.
Executive Commentary
‘This cancellation of 47 million shares is a landmark win for our shareholders, effectively removing a massive block of potential dilution and future distributions,’ said Matt Dwyer, President of Exousia Pro, Inc. ‘We are equally energized by the rapid scaling of our telehealth targets. The projected revenue from these acquisitions will provide a substantial boost to our balance sheet. Furthermore, our rebranding to Nextel Medical Corp. solidifies our unique identity in the biotech space. I look forward to providing live updates from our mediation on March 13th as we continue to advocate for the best interests of our investors.’
For investors seeking to diversify their portfolios, US stock market investment strategies can provide a range of options. Considering the Indian stock market trends and the performance of companies like Exousia Pro can help investors make informed decisions.
Conclusion
In conclusion, Exousia Pro’s recent announcements demonstrate the company’s commitment to enhancing shareholder value and expanding its commercial footprint. As the company progresses toward definitive agreements for telehealth acquisitions and rebrands as Nextel Medical Corp., Indian investors should consider the potential implications of these developments on the biotechnology industry trends and the US stock market outlook.